Related Experiment Video
Updated: Aug 25, 2025
08:12
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
5.6K
MicroRNA-125a-3p, -4530, and -92a as a Potential Circulating MicroRNA Panel for Noninvasive Pancreatic Cancer
Ali Seyed Salehi1,2, Negar Parsa-Nikoo1,2, Farnaz Roshan-Farzad1,2
1Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Disease Markers
|October 18, 2022
Summary
This study identifies a three-microRNA (miRNA) panel (miR-125a-3p, miR-4530, miR-92a-2-5p) for noninvasive pancreatic cancer (PC) diagnosis. The panel shows high diagnostic accuracy in plasma samples, offering a promising tool for early detection.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- MicroRNA (miRNA) expression alterations are implicated in pancreatic ductal adenocarcinoma (PDAC) pathogenesis.
- Previous bioinformatics analysis identified potential miRNA panels for pancreatic cancer (PC) screening.
- Accurate and noninvasive diagnostic tools for PC are crucial for improved patient outcomes.
Purpose of the Study:
- To validate a previously identified three-miRNA diagnostic panel (miR-125a-3p, miR-4530, miR-92a-2-5p) in plasma samples from PC patients.
- To assess the diagnostic performance of this miRNA panel for noninvasive PC detection.
Main Methods:
- Retrospective analysis of 142 plasma samples from individuals with and without PC.
- Quantitative reverse transcription PCR (RT-qPCR) for differential expression analysis of selected miRNAs.
- Development and evaluation of a three-miRNA panel using receiver operating characteristic (ROC) curve analysis.
Main Results:
- All three miRNAs (miR-125a-3p, miR-4530, miR-92a-2-5p) were significantly upregulated in the plasma of PC patients compared to controls.
- The developed three-miRNA panel demonstrated high diagnostic accuracy, with areas under the ROC curves (AUC) of 0.850, 0.910, and 0.86.
- The panel's diagnostic value exceeded that of individual miRNAs.
Conclusions:
- A three-miRNA signature (miR-125a-3p, miR-4530, miR-92a-2-5p) in plasma shows significant potential for noninvasive pancreatic cancer diagnosis.
- This panel represents a promising biomarker strategy for early detection and management of PC.
